Virios Therapeutics Inc Stock News

ATLANTA, GEORGIA / ACCESS Newswire / October 7, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain, today announced that its Chief Medical Officer will present an overview of the Halneuron®(tetrodotoxin) pain management research program at the 19th Annual Pain Therapeutics Summit on October 14, 2025. ...

Dogwood Therapeutics, Inc. - Special Call Company Participants Greg Duncan - Chairman & CEO R. Gendreau - Chief Medical Officer Conference Call Participants Xun Lee - H.C.

-A first-in-class LRP1 agonist, SP16 phase 1b Chemotherapy Induced Neuropathy (CIPN) Study fully funded by the National Cancer Institute, with projected patient enrollment beginning in the first half of 2026-

ATLANTA, Sept. 03, 2025 (GLOBE NEWSWIRE) --  Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announces it will participate in the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Pal...

- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track for Q4 2025 - - Low discontinuation rate (5.8%) due to adverse events in the first 38 patients completing the trial suggests Halneuron ® and placebo treatment have been generally well tolerated - - Cash on...

- Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 -

ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development‐stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, announced today that it will report second quarter 2025 financial results on Wednesday, August 13, 2025 before the open of the financial markets.

ATLANTA, June 03, 2025 (GLOBE NEWSWIRE) --  Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced that CEO, Greg Duncan, will present a corporate overview at the Sidoti Small-Cap Virtual Conference being held on Wednesday, June 11, 2025 – Thursday, Ju...